Targeting neddylation in cancer: molecular mechanisms, translational advances, and therapeutic challenges
Frontiers in Pharmacology · 29.10.2026 · 17
DOI: 10.3389/fphar.2026.1936781 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.10.2026. Verfasst von Xin Tian und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stomatology, General Hospital of Northern Theater Command, Shenyang, China. Die Arbeit nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neddylation is a ubiquitin-like post-translational modification that regulates cullin–RING ligases and selected non-cullin substrates involved in cell-cycle progression, DNA replication licensing, DNA-damage repair, apoptosis, hypoxic signaling, inflammatory responses, epithelial–mesenchymal transition, metabolic adaptation, and immune regulation. Many tumors rely on aberrant neddylation-dependent protein turnover to sustain proliferation, survival, metastatic plasticity, and therapeutic resistance, making this pathway a compelling anticancer target. This review outlines the molecular architecture of the NEDD8 cascade, encompassing NEDD8 activation, E2-mediated conjugation, E3/co-E3-facilitated ligation, deneddylation, and the central role of cullin–RING ligases as oncogenic effectors. It also examines the principal classes of neddylation-pathway inhibitors, including the first-in-class NEDD8-activating enzyme inhibitor MLN4924, newer NAE inhibitors such as TAS4464, emerging UBE2M- and UBE2F-directed approaches, DCN1/DCUN1-targeted inhibitors, and natural product-derived or other experimental compounds. Preclinical evidence across hematologic malignancies, gastrointestinal and genitourinary cancers, thoracic and head-and-neck tumors, brain tumors, and pediatric cancers indicates that neddylation inhibition can suppress tumor growth and enhance responses to chemotherapy, radiotherapy, apoptosis-targeted agents, proteasome inhibition, autophagy modulation, and immunotherapy. Nevertheless, clinical translation remains constrained by inadequate patient selection, context-dependent substrate accumulation, adaptive resistance, complex immune effects, and limited therapeutic windows. Future development should therefore move beyond empirical pan-pathway inhibition toward biomarker-guided, tumor-context-specific precision strategies integrating selective E1, E2, and E3 inhibitors, rational combination regimens, pharmacodynamic monitoring, resistance profiling, immune-state assessment, and tumor-targeted delivery systems.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Stomatology, General Hospital of Northern Theater Command, Shenyang, China.
- Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Zitieren
APA
Tian, X., Li, X., Liu, D., Min, Y., & Hu, Y. (2026). Targeting neddylation in cancer: molecular mechanisms, translational advances, and therapeutic challenges. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1936781
Vancouver
Tian X, Li X, Liu D, Min Y, Hu Y. Targeting neddylation in cancer: molecular mechanisms, translational advances, and therapeutic challenges. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1936781
BibTeX
@article{Tian2026,
author = {Tian, Xin and Li, Xinghan and Liu, Dequan and Min, Ying and Hu, Yang},
title = {Targeting neddylation in cancer: molecular mechanisms, translational advances, and therapeutic challenges},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1936781}
}
EUVIMED